Clinical Trials on Schizoaffective Disorders in United States

Total 60616 results

Amgen

Completed

Multiple Ascending Dose Study on Safety, Tolerability, and Pharmacokinetics of AMG 581 in Healthy Subjects or Subjects With Schizophrenia or Schizoaffective (MAD)

Schizophrenia or Schizoaffective Disorder

United States
Amgen

Completed

Single-ascending Dose Study With a Food-Effect Cohort to Evaluate AMG 581 (FIH)

Schizophrenia or Schizoaffective Disorder

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Recruiting

Open-label Trial Characterizing the PK of 3 SC Olanzapine Extended-release Formulations in Participants With Schizophrenia/Schizoaffective Disorder

Schizophrenia, Schizoaffective Disorder

United States
Boston University Charles River Campus

Completed

Computerized Cognitive-Behavioral Therapy for Auditory Hallucinations

Schizophrenia, Schizoaffective Disorder

United States
Hoffmann-La Roche

Terminated

A Study to Assess the Effects of RO6889450 (Ralmitaront) in Participants With Schizophrenia or Schizoaffective Disorder and Negative Symptoms

Schizophrenia, Schizoaffective Disorder

United States, Spain, Japan, Ukraine
New York State Psychiatric Institute
National Institute of Mental Health (NIMH); Columbia University

Completed

Cognitive Remediation for Coordinated Specialty Care

Schizophrenia | Schizoaffective Disorder

United States
Hoffmann-La Roche

Completed

A Trial of the Efficacy and the Safety of RO6889450 (Ralmitaront) vs Placebo in Patients With an Acute Exacerbation of Schizophrenia or Schizoaffective Disorder

Schizophrenia, Schizoaffective Disorder

United States, Japan, Ukraine, Russian Federation
Solvay Pharmaceuticals
Wyeth is now a wholly owned subsidiary of Pfizer; H. Lundbeck A/S

Completed

Switch Study of Existing Atypical Antipsychotics to Bifeprunox

Schizophrenia and Schizoaffective Disorder

Hungary, United States, Argentina, Canada, Czech Republic, Estonia, France, Latvia, Lithuania
Columbia University
National Institute of Mental Health (NIMH)

Recruiting

Effectiveness of Motivation Skills Training (MST) (MST)

Schizophrenia | Schizoaffective Disorder

United States
Beth Israel Deaconess Medical Center

Recruiting

Sodium Nitroprusside in Early Course Schizophrenia

Schizophrenia | Schizoaffective Disorder

United States
University of Pennsylvania

Withdrawn

Effectiveness and Mechanisms of Recovery Oriented Cognitive Therapy

Schizophrenia | Schizoaffective Disorder

United States
The University of Texas at Dallas

Completed

Improving Visual Attention in Schizophrenia

Schizophrenia | Schizoaffective Disorder

United States
University of Texas Southwestern Medical Center
Sunovion

Completed

Lurasidone Effects on Tissue Glutamate in Schizophrenia

Schizophrenia | Schizoaffective Disorder

United States
VA Office of Research and Development

Completed

Building Employment Skills Through Therapy for Veterans (BEST Vet)

Schizophrenia | Schizoaffective Disorder

United States
University of Maryland, Baltimore

Completed

Neuroendocrine and Immune Response to Stress in Schizophrenia (TSST)

Schizophrenia | Schizoaffective Disorder

United States
Northwestern University
Ortho-McNeil Janssen Scientific Affairs, LLC

Completed

High Dose Risperidone Consta for Patients With Schizophrenia With Poor Response to Risperidone

Schizophrenia | Schizoaffective Disorder

United States
University of Massachusetts, Worcester
National Institutes of Health (NIH)

Completed

Telmisartan as an Adjunctive Treatment for Metabolic Problems in Patients With Schizophrenia

Schizophrenia | Schizoaffective Disorder

United States
University of Massachusetts, Worcester
National Institutes of Health (NIH)

Completed

Salsalate as an Adjunctive Treatment for Patients With Schizophrenia

Schizophrenia | Schizoaffective Disorder

United States
Northwestern University
Novartis Pharmaceuticals

Terminated

Assessing the Effects of Fanapt® on Social Cognition in Schizophrenia

Schizophrenia | Schizoaffective Disorder

United States
Solvay Pharmaceuticals
Wyeth is now a wholly owned subsidiary of Pfizer; H. Lundbeck A/S

Completed

To Evaluate the Impact of Treatment Interruption on Re-initiation of Bifeprunox

Schizophrenia | Schizoaffective Disorder

United States
VA Connecticut Healthcare System
Eli Lilly and Company; Clinical Trials Network of Columbia U, Cornell U, and...

Withdrawn

Zyprexa and Task Engagement in Schizophrenia

Schizophrenia | Schizoaffective Disorder

United States
Sheppard Pratt Health System
Stanley Medical Research Institute

Completed

Artemisinin to Reduce The Symptoms of Schizophrenia

Schizophrenia | Schizoaffective Disorder

United States
University of Pittsburgh
Stanley Medical Research Institute

Completed

A Clinical Trial to Examine Effects of Atomoxetine in the Treatment of Negative Symptoms in Patients With Schizophrenia

Schizophrenia | Schizoaffective Disorder

United States
Vanderbilt University
National Alliance for Research on Schizophrenia and Depression; Abbott

Completed

Does The Addition Of Divalproex Sodium ER To An Atypical Antipsychotic Drug (APD) Improve Cognition And Psychopathology In Outpatients With Schizophrenia (SCH) Or Schizoaffective Disorder (SAD)?

Schizophrenia | Schizoaffective Disorder

United States
North Suffolk Mental Health Association

Completed

Nicotine Replacement Therapy for Smoking Cessation in Schizophrenia

Schizophrenia | Schizoaffective Disorder

United States
US Department of Veterans Affairs

Completed

Generalization of Training in Schizophrenia

Schizophrenia | Schizoaffective Disorder

United States
University of Texas Southwestern Medical Center
National Institute of Mental Health (NIMH); Beth Israel Deaconess Medical Center and other collaborators

Recruiting

CLOZAPINE Response in Biotype-1

Schizophrenia | Schizoaffective Disorder | Bipolar 1 Disorder

United States
VA Office of Research and Development
Stanford University; University of South Carolina

Completed

Improving Neurocognitive Deficits and Function in Schizophrenia With Transcranial Magnetic Stimulation

Schizophrenia | Schizoaffective Disorder

United States
Janssen Scientific Affairs, LLC

Completed

Sustainable Early Episode Clinic Study (SEEC) (SEEC)

Schizophrenia | Schizoaffective Disorder

United States
Duke University

Completed

Theta Burst Stimulation for Schizophrenia

Schizophrenia | Schizoaffective Disorder

United States
Yale University

Terminated

A Pilot Trial of Curcumin Effects on Cognition in Schizophrenia (CRC)

Schizophrenia | Schizoaffective Disorder

United States
Nathan Kline Institute for Psychiatric Research
Columbia University

Unknown

N-methyl-D-aspartic Acid (NMDA) and Cognitive Remediation in Schizophrenia

Schizophrenia | Schizoaffective Disorder

United States
US Department of Veterans Affairs

Completed

Cognitive - Behavioral Therapy

Schizophrenia | Schizoaffective Disorder

United States
Nathan Kline Institute for Psychiatric Research
Stanley Medical Research Institute

Completed

Effect of High-Dose B-Complex Vitamins on the Symptoms of Schizophrenia

Schizophrenia | Schizoaffective Disorder

United States
University of Maryland, Baltimore
National Center for Complementary and Integrative Health (NCCIH)

Recruiting

Prebiotic Treatment in People With Schizophrenia (FOCIS)

Schizophrenia | Schizoaffective Disorder

United States
Columbia University
National Institute of Mental Health (NIMH)

Completed

Motivation Skills Training for Schizophrenia (MST)

Schizophrenia | Schizoaffective Disorder

United States
Wyeth is now a wholly owned subsidiary of Pfizer

Withdrawn

Study Evaluating the Effects of Multiple Doses of NSA-789 in Subjects With Schizophrenia or Schizoaffective Disorder

Schizophrenia

United States
Sheppard Pratt Health System

Completed

Sulforaphane to Reduce Symptoms of Schizophrenia

Schizophrenia | Schizoaffective Disorder

United States
National Institute of Mental Health (NIMH)

Completed

Effects of Modafinil on Brain Function in Patients With Schizophrenia

Schizophrenia | Schizoaffective Disorder

United States
University of Maryland, Baltimore

Completed

Schizophrenia and the Gut Microbiome

Schizophrenia | Schizoaffective Disorder

United States
Emory University

Completed

Minocycline Augmentation to Clozapine

Schizophrenia | Schizoaffective Disorder

United States
New York State Psychiatric Institute
National Institute of Mental Health (NIMH); National Alliance for Research...

Terminated

Treatment of Negative Symptoms of Schizophrenia With Transcranial Magnetic Stimulation (TMS)

Schizophrenia | Schizoaffective Disorder

United States
University of Pittsburgh
National Institute of Mental Health (NIMH)

Completed

Treatment of Schizophrenia Through Internet-Based Psychoeducation

Schizophrenia | Schizoaffective Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...
Otsuka America Pharmaceutical

Completed

Broad Effectiveness: Study With Aripiprazole

Schizophrenia | Schizoaffective Disorder

United States
University of Massachusetts, Worcester

Completed

Effect of Single Dose Intranasal Insulin On Cognitive Function

Schizophrenia | Schizoaffective Disorder

United States
University of Pennsylvania
National Alliance for Research on Schizophrenia and Depression

Completed

Cognitive Therapy for Negative Symptoms and Functioning

Schizophrenia | Schizoaffective Disorder

United States
Louisiana State University Health Sciences Center...
SAM Technology & The San Francisco Brain Research Institute

Terminated

Cognitive Improvement With Aripiprazole (Abilify) in Patients With Schizophrenia (SFBRI)

Schizophrenia | Schizoaffective Disorder

United States
Vanderbilt University
National Alliance for Research on Schizophrenia and Depression; Cephalon

Completed

Effects of Armodafinil on Cognition for Patients With Schizophrenia or Schizoaffective Disorder

Schizophrenia | Schizoaffective Disorder

United States
North Suffolk Mental Health Association

Completed

A Comparison of Two Cognitive Batteries in People With Schizophrenia

Schizophrenia | Schizoaffective Disorder

United States
North Suffolk Mental Health Association
Janssen Medical Affairs

Completed

Galantamine for Cognition in People With Schizophrenia

Schizophrenia | Schizoaffective Disorder

United States

Clinical Trials on Schizoaffective Disorders in United States

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Congo, DR of

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations